Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3350521
Max Phase: Preclinical
Molecular Formula: C24H41IN7O15P3
Molecular Weight: 887.45
Molecule Type: Small molecule
Associated Items:
ID: ALA3350521
Max Phase: Preclinical
Molecular Formula: C24H41IN7O15P3
Molecular Weight: 887.45
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CN(CCCCN(C)c1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O)C(=O)CCCCCNC(=O)CI
Standard InChI: InChI=1S/C24H41IN7O15P3/c1-30(18(34)8-4-3-5-9-26-17(33)12-25)10-6-7-11-31(2)22-19-23(28-14-27-22)32(15-29-19)24-21(36)20(35)16(45-24)13-44-49(40,41)47-50(42,43)46-48(37,38)39/h14-16,20-21,24,35-36H,3-13H2,1-2H3,(H,26,33)(H,40,41)(H,42,43)(H2,37,38,39)/t16-,20-,21-,24-/m1/s1
Standard InChI Key: PVFPWZUDHBIIIB-FZGCSJHNSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 887.45 | Molecular Weight (Monoisotopic): 887.0918 | AlogP: 0.58 | #Rotatable Bonds: 21 |
Polar Surface Area: 305.76 | Molecular Species: ACID | HBA: 16 | HBD: 7 |
#RO5 Violations: 3 | HBA (Lipinski): 22 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 0.90 | CX Basic pKa: 4.60 | CX LogP: -3.30 | CX LogD: -8.45 |
Aromatic Rings: 2 | Heavy Atoms: 50 | QED Weighted: 0.04 | Np Likeness Score: 0.27 |
1. Hampton A, Picker D, Nealy KA, Maeda M.. (1982) Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 4. Interactions of adenosine 5'-triphosphate derivatives with adenylate kinases from Escherichia coli and rat tissues., 25 (4): [PMID:6279845] [10.1021/jm00346a010] |
2. Hampton A, Patel AD, Chawla RR, Kappler F, Hai TT.. (1982) Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 5. Interactions of adenosine 5'-triphosphate derivatives with rat pyruvate kinases, Escherichia coli thymidine kinase, and yeast and rat hexokinases., 25 (4): [PMID:7040662] [10.1021/jm00346a011] |
Source(1):